Anitcancer Activity of Vitamin D Analogs

作者: Candace S. Johnson , Milan R. Uskoković , Donald L. Trump , Robert H. Getzenberg

DOI: 10.1007/978-1-4757-2861-3_25

关键词:

摘要: From its discovery in 1920 to the late 1960s, vitamin D was considered function as a nutritional cofactor for biologic processes related calcium metabolism. Discovery and chemical characterization of plasma metabolites 25-hydroxy D3 [25(OH)D3] 1,25-dihydroxy [1,25(OH)2D3] led recognition true significance precursor hormone, biosynthesis which is tightly regulated, case other steroid hormones (Scheme 1). During last 10 years, significant progress has been made at defining molecular mechanism 1,25(OH)2D3 activity various cellular systems. hormone plays an essential role host involved calcium-phosphate homeostasis, inhibition cell growth, induction differentiation. It now well established that this hormonally active form generates responses by two distinct mechanistic pathways, via regulation gene transcriptions mediated 1,25(OH)2D3-specific nuclear receptors [the receptor (VDR)], nongenomic mode initiated membranes. The genomic effects are especially portrayed multifaceted bone-forming processes, parathyroid release, differentiation myeloid leukemia cells, proliferation large number cancer lines, such breast, prostate, colon. As therapeutic agents, some analogs being used treatment renal osteodystrophy, secondary hyperparathyroidism, osteoporosis, psoriasis, scleroderma. These compounds also have potential be solid tumors based on vivo results discussed chapter. immunosuppressive defined their downregulation interleukin-12 (IL-12), interferon-γ (INF-γ), IL-2 it supported disease suppression models experimental autoimmune encephalomyelitis, diabetes lupus (1).

参考文章(17)
George P. Studzinski, Amarjit K. Bhandal, Zamir S. Brelvi, Cell Cycle Sensitivity of HL-60 Cells to the Differentiation-inducing Effects of 1-α,25-Dihydroxyvitamin D3 Cancer Research. ,vol. 45, pp. 3898- 3905 ,(1985)
An-Ya S. Wu, Nobuo Ikekawa, Yoshiro Kobayashi, Makoto Kawai, Katsuhiko Iseki, Yoko Tanaka, Inhibition of HT-29 Human Colon Cancer Growth under the Renal Capsule of Severe Combined Immunodeficient Mice by an Analogue of 1,25-Dihydroxyvitamin D3, DD-003 Cancer Research. ,vol. 54, pp. 5148- 5153 ,(1994)
Thomas A. Brasitus, Michael D. Sitrin, Marc Bissonnette, Ramesh K. Wali, John Hart, Sharad Khare, 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a Noncalcemic Analogue of 1α,25-Dihydroxyvitamin D3, Inhibits Azoxymethane-induced Colonic Tumorigenesis Cancer Research. ,vol. 55, pp. 3050- 3054 ,(1995)
George P. Studzinski, Qing Mei Wang, Jennifer B. Jones, Cyclin-dependent Kinase Inhibitor p27 as a Mediator of the G1-S Phase Block Induced by 1,25-Dihydroxyvitamin D3 in HL60 Cells Cancer Research. ,vol. 56, pp. 264- 267 ,(1996)
John A. Eisman, Peter J. M. Tutton, David H. Barkla, Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Research. ,vol. 47, pp. 21- 25 ,(1987)
Gary G Schwartz, Christopher C Hill, Theresa A Oeler, Michael J Becich, Robert R Bahnson, None, 1,25-dihydroxy-16-ene-23-yne-vitamin d3 and prostate cancer cell proliferation in vivo* Urology. ,vol. 46, pp. 365- 369 ,(1995) , 10.1016/S0090-4295(99)80221-0
Kay W. Colston, Alan G. Mackay, Sharon Y. James, Lise Binderup, Surinder Chander, R.Charles Coombes, EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro Biochemical Pharmacology. ,vol. 44, pp. 2273- 2280 ,(1992) , 10.1016/0006-2952(92)90669-A
Robert H. Getzenberg, Benjamin W. Light, Paul E. Lapco, Badrinath R. Konety, Ajay K. Nangia, James S. Acierno, Rajiv Dhir, Zoya Shurin, Roger S. Day, Donald L. Trump, Candace S. Johnson, Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system Urology. ,vol. 50, pp. 999- 1006 ,(1997) , 10.1016/S0090-4295(97)00408-1